Cardiovascular Data To Propel Jardiance Ahead Of Rivals
This article was originally published in Scrip
Executive Summary
The sodium-glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/ Eli Lilly) is expected to experience a significant increase in uptake in the type 2 diabetes market after the presentation of its much-anticipated cardiovascular (CV) outcomes data at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.
You may also be interested in...
Surprise German Decision Boosts Jardiance Pricing Potential
Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.
Lilly Executes Growth Strategy As New Products Drive Sales Gains
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.